Top

Breast Cancer

Published in:

01-11-2014 | Rapid Communication

Near-infrared optical imaging of cancer vascular remodeling after antiangiogenic therapy

Authors: Shigeto Ueda, Toshiaki Saeki

Published in: Breast Cancer | Issue 6/2014

Abstract

Background

Near-infrared diffuse optical imaging (DOSI) has been recently accepted as a method to assess tumor vascularity and oxygenation by measuring tissue hemoglobin (Hb) concentration. It is expected that DOSI could be used to monitor changes in vascularity after antiangiogenic therapy.

Methods

A patient with advanced breast cancer was treated with single-agent bevacizumab followed by addition of weekly paclitaxel to it. DOSI was performed in the tumor-bearing breast and contralateral normal breast at baseline, 3, 6, 12, 24 h, and then daily for 1 week. Images of a tumor-to-normal ratio of tHb (rtHb) were constructed for identifying a tumor lesion.

Results

Serial images of rtHb showed a tumor lesion which corresponded to a hot spot. The level of rtHb rapidly decreased within several hours after administration of single-agent bevacizumab and then persisted at low levels during treatment. From day 2, the value of rtHb gradually increased and peaked on day 5.

Conclusion

This trend may be explained considering sequential images of rtHb indicating the inhibition of angiogenesis due to antiangiogenic therapy. We conducted a clinical study using single-agent bevacizumab followed by neoadjuvant chemotherapy in primary breast cancer patients to understand vascular remodeling after antiangiogenic agent at very early time points using DOSI.

Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science. 2005;307(5706):58–62.CrossRefPubMed

Goel S, Duda DG, Xu L, Munn LL, Boucher Y, Fukumura D, Jain RK. Normalization of the vasculature for treatment of cancer and other diseases. Physiol Rev. 2011;91(3):1071–121.CrossRefPubMedCentralPubMed

Cerussi A, Shah N, Hsiang D, Durkin A, Butler J, Tromberg BJ. In vivo absorption, scattering, and physiologic properties of 58 malignant breast tumors determined by broadband diffuse optical spectroscopy. J Biomed Opt. 2006;11(4):044005.CrossRefPubMed

Tromberg BJ, Cerussi A, Shah N, Compton M, Durkin A, Hsiang D, Butler J, Mehta R. Imaging in breast cancer: diffuse optics in breast cancer: detecting tumors in pre-menopausal women and monitoring neoadjuvant chemotherapy. Breast Cancer Res. 2005;7(6):279–85.CrossRefPubMedCentralPubMed

Ueda Y, Yoshimoto K, Ohmae E, Suzuki T, Yamanaka T, Yamashita D, Ogura H, Teruya C, Nasu H, Ima E, et al. Time-resolved optical mammography and its preliminary clinical results. Technol Cancer Res Treat. 2011;10(5):393–401.PubMed

Ueda S, Nakamiya N, Matsuura K, Shigekawa T, Sano H, Hirokawa E, Shimada H, Suzuki H, Oda M, Yamashita Y, et al. Optical imaging of tumor vascularity associated with proliferation and glucose metabolism in early breast cancer: clinical application of total hemoglobin measurements in the breast. BMC Cancer. 2013;13(1):514.CrossRefPubMedCentralPubMed

Zwick S, Strecker R, Kiselev V, Gall P, Huppert J, Palmowski M, Lederle W, Woenne EC, Hengerer A, Taupitz M, et al. Assessment of vascular remodeling under antiangiogenic therapy using DCE-MRI and vessel size imaging. J Magn Reson Imaging JMRI. 2009;29(5):1125–33.CrossRef

De Bruyne S, Van Damme N, Smeets P, Ferdinande L, Ceelen W, Mertens J, Van de Wiele C, Troisi R, Libbrecht L, Laurent S, et al. Value of DCE-MRI and FDG-PET/CT in the prediction of response to preoperative chemotherapy with bevacizumab for colorectal liver metastases. Br J Cancer. 2012;106(12):1926–33.CrossRefPubMedCentralPubMed

Bartlett RM, Beattie BJ, Naryanan M, Georgi JC, Chen Q, Carlin SD, Roble G, Zanzonico PB, Gonen M, O’Donoghue J, et al. Image-guided PO₂ probe measurements correlated with parametric images derived from 18F-fluoromisonidazole small-animal PET data in rats. J Nucl Med Off Publ Soc Nucl Med. 2012;53(10):1608–15.

10.

Cheng J, Lei L, Xu J, Sun Y, Zhang Y, Wang X, Pan L, Shao Z, Zhang Y, Liu G. 18F-fluoromisonidazole PET/CT: a potential tool for predicting primary endocrine therapy resistance in breast cancer. J Nucl Med Off Publ Soc Nucl Med. 2013;54(3):333–40.

11.

Roblyer D, Ueda S, Cerussi A, Tanamai W, Durkin A, Mehta R, Hsiang D, Butler JA, McLaren C, Chen WP, et al. Optical imaging of breast cancer oxyhemoglobin flare correlates with neoadjuvant chemotherapy response one day after starting treatment. Proc Natl Acad Sci USA. 2011;108(35):14626–31.CrossRefPubMedCentralPubMed

12.

Zhu Q, DeFusco PA, Ricci A Jr, Cronin EB, Hedge PU, Kane M, Tavakoli B, Xu Y, Hart J, Tannenbaum SH. Breast cancer: assessing response to neoadjuvant chemotherapy by using US-guided near-infrared tomography. Radiology. 2013;266(2):433–42.CrossRefPubMedCentralPubMed

Title: Near-infrared optical imaging of cancer vascular remodeling after antiangiogenic therapy
Authors: Shigeto Ueda
Toshiaki Saeki
Publication date: 01-11-2014
Publisher: Springer Japan
Published in: Breast Cancer / Issue 6/2014
Print ISSN: 1340-6868
Electronic ISSN: 1880-4233
DOI: https://doi.org/10.1007/s12282-014-0534-2

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 6/2014

Psychosocial distress among young breast cancer survivors: implications for healthcare providers

Immediate transverse rectus abdominis musculocutaneous (TRAM) flap breast reconstruction in underweight Asian patients

Toxicity and quality of life of Korean breast cancer patients treated with docetaxel-containing chemotherapy without primary G-CSF prophylaxis

Clinicopathological features of young patients (<35 years of age) with breast cancer in a Japanese Breast Cancer Society supported study

Osteopoikilosis masquerading as osseous metastases in breast cancer

An osteogenesis imperfecta case with breast cancer

Keynote webinar | Spotlight on antibody–drug conjugates in cancer